• EZ Cap™ Firefly Luciferase mRNA for LNP Assays

  2026-08-08

  EZ Cap™ Firefly Luciferase mRNA enables sensitive, mechanistically interpretable reporter assays. This article shows how Cap1 architecture, transcript handling, LNP size, cellular ATP, and assay timing collectively determine the meaning of a bioluminescence signal.

• FAK Inhibitor 14 in EMT Research

  2026-08-07

  FAK Inhibitor 14 provides a practical pharmacological test of FAK-dependent adhesion, migration, and EMT signaling in cholesterol-conditioned ovarian cancer models. This workflow combines pathway readouts with functional assays to distinguish direct signaling effects from changes in proliferation or cell viability.

• Amyloid Beta-peptide (25-35): Applied Neurotoxicity Modeling

  2026-08-07

  Amyloid Beta-peptide (25-35) (human) empowers robust, reproducible modeling of Alzheimer's disease neurotoxicity and microglial polarization. This article delivers actionable protocols, troubleshooting strategies, and insights from the latest mechanistic research, driving innovation in neurodegenerative disease studies.

• UTP Solution: Advancing In Vitro Transcription and RNA Workf

  2026-08-06

  UTP Solution (100 mM) empowers researchers with ultrapure, DNase/RNase-free uridine-5'-triphosphate trisodium salt for high-fidelity RNA synthesis and metabolic assays. Discover how this reagent enhances experimental reliability, streamlines sensitive protocols, and addresses common troubleshooting challenges in cutting-edge molecular biology.

• Mechanistic Cell Fate Analysis: Strategic AO/PI Staining for

  2026-08-06

  Explore the mechanistic power and translational impact of the AO/PI Double Staining Kit in advanced cell viability and apoptosis detection. This article bridges recent glioma organoid modeling breakthroughs with practical, protocol-driven guidance, offering strategic insights for researchers aiming to elevate experimental rigor and translational relevance in oncology and drug screening workflows.

• Histone H4K12 Lactylation Drives TNBC via SLFN5 Suppression

  2026-08-05

  This study reveals that histone H4K12 lactylation, induced by elevated lactate in triple-negative breast cancer (TNBC), promotes tumor progression by downregulating the tumor suppressor SLFN5. It establishes a mechanistic link between tumor metabolism and epigenetic reprogramming, and demonstrates that inhibiting lactate production—using metabolic inhibitors such as sodium oxamate—can reverse this malignancy-driving axis.

• Pharmacological Induction of Embryonic Dormancy via mTOR Inh

  2026-08-05

  This article summarizes a protocol for inducing a reversible, dormancy-like state in mammalian embryonic cells and pluripotent stem cells using pharmacological mTOR inhibition. The approach enables noninvasive, scalable studies of diapause and cellular dormancy, with implications for reproductive biology and developmental research.

• β-Elemene Suppresses Adipogenesis via AMPK Activation in 3T3

  2026-08-04

  This study demonstrates that β-Elemene inhibits adipogenesis in 3T3-L1 preadipocytes by activating the AMPK pathway, reversing insulin resistance-induced lipid accumulation. These findings highlight β-Elemene's potential as a molecular tool for probing obesity mechanisms and developing metabolic research models.

• WY-14643 (Pirinixic Acid): Applied Workflows in Metabolic Re

  2026-08-04

  WY-14643 (Pirinixic Acid) stands out as a selective PPARα agonist, streamlining advanced metabolic and inflammation studies with robust reproducibility. This guide translates cutting-edge research into practical protocols, troubleshooting strategies, and assay enhancements for metabolic disorder and tumor microenvironment research.

• Dronedarone (Multaq): Mechanistic Insights for AF Research

  2026-08-03

  Explore the molecular mechanisms and research applications of Dronedarone (Multaq) as an antiarrhythmic agent for atrial fibrillation. This article delivers unique analytical depth, bridging pharmacological action with advanced assay design.

• PP2A-Mediated Autophagy Drives Drug Resistance in Candida Bi

  2026-08-03

  The referenced study reveals how protein phosphatase 2A (PP2A) modulates autophagy and biofilm-associated drug resistance in Candida albicans. By dissecting the phosphorylation of key ATG proteins, the work highlights a potential regulatory axis for overcoming antifungal resistance, informing future antifungal strategies and biofilm research.

• Innovative In Vitro Metrics for Cancer Drug Response Evaluat

  2026-08-02

  The referenced dissertation introduces a refined framework for evaluating anti-cancer drug responses in vitro, distinguishing between cell proliferation arrest and cell death using relative and fractional viability metrics. This approach enables more precise assessment of drug mechanisms and could improve the translational relevance of preclinical cancer research.

• Lumiracoxib in COX-2 Selective Inhibition Assays: Advanced W

  2026-08-01

  Lumiracoxib empowers researchers to dissect COX-2-mediated pathways in inflammation models with high selectivity and reproducibility. This guide details optimized protocols, troubleshooting, and translational insights from recent muscle ischemia studies, illustrating how precise pathway modulation with Lumiracoxib yields actionable data that can't be achieved with less selective inhibitors.

• FAK Inhibitor 14: Optimized Workflows and Troubleshooting in

  2026-07-31

  FAK Inhibitor 14 (benzene-1,2,4,5-tetraamine tetrahydrochloride) enables precise dissection of FAK signaling in advanced cancer models, including cholesterol-resistant ovarian cancer. This guide delivers protocol enhancements, troubleshooting strategies, and actionable insights to maximize reproducibility and data quality in tumor metastasis research.

• WY-14643 (Pirinixic Acid): Reliable PPARα Agonism in Metabol

  2026-07-31

  This article provides a scenario-driven, evidence-based exploration of WY-14643 (Pirinixic Acid, SKU A4305), emphasizing its reproducibility and validated performance in cell viability, lipid metabolism, and inflammation assays. Researchers will find practical insights, protocol parameters, and comparative guidance to optimize metabolic disorder research using this selective PPARα agonist.

16137 records 1/1076 page Next 12345 下5页 Last page